G1 Therapeutics dives as Q3 cancer drug sales miss estimates

G1 Therapeutics

02/11/2022 16:27

** Cancer therapy developer G1 Therapeutics Inc's  GTHX.O 
shares down 24.8% at $8.21, biggest pct. drop in over 2-1/2
years 
    ** Co reports Q3 sales of $8.3 million from its small-cell
lung cancer drug, Cosela, missing estimates of $10.8 million,
according to Refinitiv data
    ** Brokerage Roth Capital Partners cuts PT to $34 from $35
and lowers 2023 Cosela sales estimates to $70 mln from $81.2 mln
    ** Co also reports that its drug reduces adverse events in
combination with sacituzumab, a drug for the treatment of adults
with triple-negative breast cancer 
    ** Including session loss, stock has lost nearly a fifth of
its value compared with a ~13% decline in the Nasdaq
Biotechnology index  .NBI 
 (Reporting by Sriparna Roy)
 ((Sriparna.roy@thomsonreuters.com))